S&P 500   4,336.30 (-1.67%)
DOW   34,065.17 (-0.87%)
QQQ   343.86 (-2.67%)
AAPL   158.11 (-2.17%)
MSFT   287.04 (-3.15%)
FB   300.52 (-2.65%)
GOOGL   2,558.23 (-2.21%)
AMZN   2,804.77 (-2.98%)
TSLA   915.19 (-1.59%)
NVDA   223.99 (-4.16%)
BABA   119.47 (-0.75%)
NIO   23.69 (-4.74%)
AMD   111.49 (-4.33%)
CGC   7.12 (-3.78%)
MU   80.80 (-2.59%)
GE   89.99 (-7.14%)
T   25.91 (-1.63%)
F   19.76 (-3.09%)
DIS   134.43 (-2.20%)
AMC   16.14 (-3.00%)
PFE   51.61 (+0.14%)
ACB   4.11 (-4.86%)
BA   200.35 (-1.89%)
S&P 500   4,336.30 (-1.67%)
DOW   34,065.17 (-0.87%)
QQQ   343.86 (-2.67%)
AAPL   158.11 (-2.17%)
MSFT   287.04 (-3.15%)
FB   300.52 (-2.65%)
GOOGL   2,558.23 (-2.21%)
AMZN   2,804.77 (-2.98%)
TSLA   915.19 (-1.59%)
NVDA   223.99 (-4.16%)
BABA   119.47 (-0.75%)
NIO   23.69 (-4.74%)
AMD   111.49 (-4.33%)
CGC   7.12 (-3.78%)
MU   80.80 (-2.59%)
GE   89.99 (-7.14%)
T   25.91 (-1.63%)
F   19.76 (-3.09%)
DIS   134.43 (-2.20%)
AMC   16.14 (-3.00%)
PFE   51.61 (+0.14%)
ACB   4.11 (-4.86%)
BA   200.35 (-1.89%)
S&P 500   4,336.30 (-1.67%)
DOW   34,065.17 (-0.87%)
QQQ   343.86 (-2.67%)
AAPL   158.11 (-2.17%)
MSFT   287.04 (-3.15%)
FB   300.52 (-2.65%)
GOOGL   2,558.23 (-2.21%)
AMZN   2,804.77 (-2.98%)
TSLA   915.19 (-1.59%)
NVDA   223.99 (-4.16%)
BABA   119.47 (-0.75%)
NIO   23.69 (-4.74%)
AMD   111.49 (-4.33%)
CGC   7.12 (-3.78%)
MU   80.80 (-2.59%)
GE   89.99 (-7.14%)
T   25.91 (-1.63%)
F   19.76 (-3.09%)
DIS   134.43 (-2.20%)
AMC   16.14 (-3.00%)
PFE   51.61 (+0.14%)
ACB   4.11 (-4.86%)
BA   200.35 (-1.89%)
S&P 500   4,336.30 (-1.67%)
DOW   34,065.17 (-0.87%)
QQQ   343.86 (-2.67%)
AAPL   158.11 (-2.17%)
MSFT   287.04 (-3.15%)
FB   300.52 (-2.65%)
GOOGL   2,558.23 (-2.21%)
AMZN   2,804.77 (-2.98%)
TSLA   915.19 (-1.59%)
NVDA   223.99 (-4.16%)
BABA   119.47 (-0.75%)
NIO   23.69 (-4.74%)
AMD   111.49 (-4.33%)
CGC   7.12 (-3.78%)
MU   80.80 (-2.59%)
GE   89.99 (-7.14%)
T   25.91 (-1.63%)
F   19.76 (-3.09%)
DIS   134.43 (-2.20%)
AMC   16.14 (-3.00%)
PFE   51.61 (+0.14%)
ACB   4.11 (-4.86%)
BA   200.35 (-1.89%)
NASDAQ:INO

Inovio Pharmaceuticals Stock Forecast, Price & News

$3.81
-0.11 (-2.81%)
(As of 01/25/2022 11:17 AM ET)
Add
Compare
Today's Range
$3.61
$3.98
50-Day Range
$3.92
$7.40
52-Week Range
$3.46
$19.00
Volume
78,176 shs
Average Volume
4.54 million shs
Market Capitalization
$801.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.49
30 days | 90 days | 365 days | Advanced Chart
Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Inovio Pharmaceuticals logo

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Headlines

Inovio Pharmaceuticals (NASDAQ:INO) Sets New 52-Week Low at $3.80
January 24, 2022 |  americanbankingnews.com
Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals
January 21, 2022 |  markets.businessinsider.com
Inovio Pharmaceuticals (NASDAQ:INO) Reaches New 1-Year Low at $4.44
January 18, 2022 |  americanbankingnews.com
Inovio Pharmaceuticals (NASDAQ:INO) Shares Gap Down to $4.79
January 14, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INO
Employees
262
Year Founded
1979

Sales & Book Value

Annual Sales
$7.41 million
Book Value
$2.47 per share

Profitability

Net Income
$-166.41 million
Net Margins
-3,391.88%
Pretax Margin
-3,355.72%

Debt

Price-To-Earnings

Miscellaneous

Free Float
204,285,000
Market Cap
$801.57 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/25/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

726th out of 1,415 stocks

Surgical & Medical Instruments Industry

74th out of 130 stocks

Analyst Opinion: 3.1Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

Is Inovio Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals
or view top-rated stocks.

How has Inovio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INO shares have decreased by 54.1% and is now trading at $3.84.
View which stocks have been most impacted by COVID-19
.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Inovio Pharmaceuticals
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.04. The biopharmaceutical company earned $0.29 million during the quarter, compared to analyst estimates of $0.19 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 44.10% and a negative net margin of 3,391.88%. During the same period last year, the business posted ($0.22) EPS.
View Inovio Pharmaceuticals' earnings history
.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

6 brokerages have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their forecasts range from $6.00 to $35.00. On average, they expect Inovio Pharmaceuticals' share price to reach $12.60 in the next twelve months. This suggests a possible upside of 228.1% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • J. Joseph Kim, President, Chief Executive Officer & Director
  • Jacqueline E. Shea, Chief Operating Officer & Executive Vice President
  • Peter D. Kies, Chief Financial Officer
  • Stephen Kemmerrer, Senior Vice President-Engineering Development
  • Kate E. Broderick, Senior Vice President-Research & Development

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Green Alpha Advisors LLC (0.03%), Aries Wealth Management (0.03%), Cutler Group LP (0.00%) and Stratos Wealth Partners LTD. (0.01%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends for Inovio Pharmaceuticals
.

Which major investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including Stratos Wealth Partners LTD.. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies, and Simon X Benito.
View insider buying and selling activity for Inovio Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Inovio Pharmaceuticals stock?

INO stock was acquired by a variety of institutional investors in the last quarter, including Aries Wealth Management, Cutler Group LP, and Green Alpha Advisors LLC.
View insider buying and selling activity for Inovio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $3.84.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals has a market capitalization of $807.88 million and generates $7.41 million in revenue each year. The biopharmaceutical company earns $-166.41 million in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals employs 262 workers across the globe.

When was Inovio Pharmaceuticals founded?

Inovio Pharmaceuticals was founded in 1979.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

Where are Inovio Pharmaceuticals' headquarters?

Inovio Pharmaceuticals is headquartered at 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at [email protected], or via fax at 267-440-4242.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.